U.S. markets open in 7 hours 4 minutes
  • S&P Futures

    4,088.25
    +7.00 (+0.17%)
     
  • Dow Futures

    34,601.00
    +2.00 (+0.01%)
     
  • Nasdaq Futures

    12,057.75
    +15.50 (+0.13%)
     
  • Russell 2000 Futures

    1,896.10
    +8.60 (+0.46%)
     
  • Crude Oil

    80.33
    -0.22 (-0.27%)
     
  • Gold

    1,794.20
    +34.30 (+1.95%)
     
  • Silver

    22.44
    +0.66 (+3.03%)
     
  • EUR/USD

    1.0459
    +0.0051 (+0.49%)
     
  • 10-Yr Bond

    3.7030
    0.0000 (0.00%)
     
  • Vix

    20.58
    -1.31 (-5.98%)
     
  • GBP/USD

    1.2103
    +0.0041 (+0.34%)
     
  • USD/JPY

    136.0230
    -2.0570 (-1.49%)
     
  • BTC-USD

    17,112.77
    +233.46 (+1.38%)
     
  • CMC Crypto 200

    405.36
    +4.66 (+1.16%)
     
  • FTSE 100

    7,573.05
    +61.05 (+0.81%)
     
  • Nikkei 225

    28,226.08
    +257.09 (+0.92%)
     

ANI Pharmaceuticals Down 25% After Earnings Miss

By Sam Boughedda

Investing.com -- ANI Pharmaceuticals Inc (NASDAQ:ANIP) shares fell 25% on Tuesday after reporting its fourth-quarter and full-year earnings that saw earnings per share fail to beat analyst estimates.

The Baudette, Minnesota-based company announced earnings per share of 54 cents on revenue of $60.93 million. Analysts polled by Investing.com anticipated EPS of 75 cents on revenue of $56.3 million.

The company also reported full-year 2021 revenues of $216.1 million.

“The past few months have been an exciting time for ANI as we completed the build out of our Rare Disease business team. Our senior leadership has experience across over 20 Rare Disease launches and 75% of our high-performing sales colleagues have won President’s Club or equivalent in the past few years," said Nikhil Lalwani, president and CEO of ANI.

"The strengthening of our balance sheet through our debt refinancing and recent $75 million equity raise, position us well to deliver long-term sustainable growth,” concluded Lalwani.

Related Articles

ANI Pharmaceuticals Down 25% After Earnings Miss

Volatility exchange traded note soars after Barclays suspends share issuance

U.S. Senate approves bill that would make Daylight Savings Time permanent in 2023